Abstract
HPV related OPSCC has a distinct behavior and improved outcome. As immunotherapy has recently evolved into a new standard for advanced (SCCHN), trials for high-risk SCCHN have trended to encompass both HPV related and unrelated diseases. In this invited editorial, we question the wisdom of this approach and argue for the design of trials focused specifically on HPV related locally advanced oropharyngeal squamous cell carcinoma as a unique disease entity.
Highlights
HPV related OPSCC has a distinct behavior and improved outcome
As immunotherapy has recently evolved into a new standard for advanced HPV related and unrelated squamous cell carcinoma of the head and neck (SCCHN) [7], trials for high-risk SCCHN have trended to encompass both diseases
* Correspondence: nfsaba@emory.edu 1Winship Cancer Institute, Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, 1365Clifton Road, building C, Atlanta, GA 30322, USA Full list of author information is available at the end of the article include and may not be limited to, the apparent comparability in prognosis of the two diseases observed in older studies such as RTOG 0129 and 0522, in addition to the ardent desire in reaching rapid registration of novel agents in the competitive immunotherapy realm
Summary
HPV related OPSCC has a distinct behavior and improved outcome. As immunotherapy has recently evolved into a new standard for advanced (SCCHN), trials for high-risk SCCHN have trended to encompass both HPV related and unrelated diseases. As immunotherapy has recently evolved into a new standard for advanced HPV related and unrelated squamous cell carcinoma of the head and neck (SCCHN) [7], trials for high-risk SCCHN have trended to encompass both diseases.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
